Filter
56
Featured
11
4
Language
Document type
22
14
7
5
3
1
1
1
1
1
Countries / Regions
8
3
2
1
1
Authors & Publishers
Publication Years
Category
10
4
1
1
Toolboxes
19
14
9
9
5
5
5
4
4
4
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Demographic and socioeconomic data Progress towards HIV testing and treatment cascade targets by 2025 (2023) Health sector cascade (2023) Estimated number of people newly infected with HIV
AIDS 2024, 38:1579–1588. Treatment interruptions are a barrier to successful antiretroviral therapy (ART). 'Fresh start messages', which leverage significant days on the calendar (e.g., new year, public holiday) in order to prompt action, have the potential to encourage people with HIV (PWH) to re
...
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment.
CDC leads an international surveillance effort to estimate the occurrence of HIV drug resistance among people with HIV who are taking dolutegravir (DTG)-based treatments. This surveillance effort utilizes Cyclical Acquired HIV Drug Resistance Surveillance (CADRE), a laboratory-based HIV drug resista
...
JAMA. 2025;333(7):609–628. doi:10.1001/jama.2024.24543
The emergence of high-level dolutegravir resistance was extremely rare in people switched to first-line dolutegravir-based treatment in Zambia and Malawi, a large prospective study has found.
Journal of the International AIDS Society 2024, 27:e26233.
Most adult ART clients in South Africa were satisfied with their care, but those enrolled in DSD models expressed slightly greater satisfaction than those remaining in conventional care. Efforts should focus on enrolling more eligible patie
...
During ARV drug pressure the HIV-1 RT is able to develop resistance to these drugs by generating mutations
What is new in this guideline. Fact Sheet
Annexure 6 National Guidelines South Africa 2023
Southern African Journal of HIV Medicine
This report aims to provide countries and suppliers with estimates of the global market for antiretroviral (ARV) medicines in low- and middle-income countries for 2021–2025. The report includes estimates of the global demand for active pharmaceutical ingredients (APIs) and ARV formulations for adu
...
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi
...
Despite progress in improving antiretroviral therapy (ART) for people with HIV in Malawi, the burden of HIV infections and HIV treatment outcomes among key populations is suboptimal. Client-centered differentiated service delivery approaches may facilitate addressing HIV prevention and treatment nee
...
ATIC Newsletter, Vol 15, Issue 1,
February 2022.
These guidelines, produced in 2022 by the Uganda Ministry of Health, provide guidance on the diagnosis of HIV, the care of people living with HIV, and the use of antiretroviral drugs for treating and preventing HIV infection, including injectable cabotegravir and the dapivirine vaginal ring.
what lessons can we take from the last few decades of health behaviour change efforts as we enter the era of HIV prevention pills, rings and injections?
J Int AIDS Soc. 2022 Nov;25(11):e25970. doi: 10.1002/jia2.25970. PMID: 36377082; PMCID: PMC9663860. These reassuring findings suggest that dolutegravir and raltegravir are effective and safe as preferred regimens in children and adolescents living with HIV. With the rollout of dolutegravir in paedia
...
Southern African HIV Clinicians Society (SAHCS) Clinical Update, May 2022
